Literature DB >> 326398

Studies on the prostate and testis as immunologically privileged sites.

W F Whitmore, R F Gittes.   

Abstract

The immunology of the prostate and testis was studied by observing allograft survival in rats and by measuring humoral antibody and delayed hypersensitivity responses to tissue antigens in the rabbit. The delayed hypersensitivity response to tissue antigen(s) was definitely diminished in those organs without demonstrable afferent lymphatics (ie, prostate, anterior eye chamber) while the humoral response was unaffected. Allograft survival in the rat showed prolonged survival in the testis and anterior eye chamber with intermediate survival in the prostate and muscle and abbreviated survival of orthotopic grafts. The extraordinary incidence of prostatic carcinoma with increasing age is discussed in light of these data. The apparent paradox of the testis as an immunologically privileged site remains unexplained.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 326398

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  9 in total

1.  Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model.

Authors:  Tullia C Bruno; Cristin Rothwell; Joseph F Grosso; Derese Getnet; Hung Rong Yen; Nicholas M Durham; George Netto; Drew M Pardoll; Charles G Drake
Journal:  Prostate       Date:  2011-07-14       Impact factor: 4.104

2.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

Authors:  Charles G Drake; Amy D H Doody; Marianne A Mihalyo; Ching-Tai Huang; Erin Kelleher; Sowmya Ravi; Edward L Hipkiss; Dallas B Flies; Eugene P Kennedy; Meixiao Long; Patrick W McGary; Lee Coryell; William G Nelson; Drew M Pardoll; Adam J Adler
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

Review 3.  Immunotherapy for the treatment of prostate cancer.

Authors:  Giuseppe Di Lorenzo; Carlo Buonerba; Philip W Kantoff
Journal:  Nat Rev Clin Oncol       Date:  2011-05-24       Impact factor: 66.675

Review 4.  Immunotherapy for prostate cancer: an emerging treatment modality.

Authors:  Charles G Drake
Journal:  Urol Clin North Am       Date:  2010-02       Impact factor: 2.241

Review 5.  Stromal cell-based immunotherapy in transplantation.

Authors:  Ronald Charles; Lina Lu; Shiguang Qian; John J Fung
Journal:  Immunotherapy       Date:  2011-12       Impact factor: 4.196

6.  Testisimmune privilege - Assumptions versus facts.

Authors:  G Kaur; P Mital; J M Dufour
Journal:  Anim Reprod       Date:  2013-01       Impact factor: 1.807

7.  Genetically engineered immune privileged Sertoli cells: A new road to cell based gene therapy.

Authors:  Gurvinder Kaur; Charles R Long; Jannette M Dufour
Journal:  Spermatogenesis       Date:  2012-01-01

8.  Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer.

Authors:  Wen-Kun Bai; Wei Zhang; Bing Hu
Journal:  Onco Targets Ther       Date:  2018-03-06       Impact factor: 4.147

Review 9.  Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?

Authors:  Bing-Juin Chiang; Hann-Chorng Kuo; Chun-Hou Liao
Journal:  Toxins (Basel)       Date:  2019-09-19       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.